Page 4 - Phouman Ashrafian News Today : Breaking News, Live Updates & Top Stories | Vimarsana

French pharma giant Sanofi buys San Diego biotech for $2 2B

The deal gives Sanofi access to Inhibrx's therapy for a genetic disorder that raises a patient's risk for lung cancer and other disease

San diegoUnited statesPhouman ashrafianAmbrx biopharmaMark lappeInhibrx biosciences incBristol myers squibbSan diego based inhibrxInhibrx biosciencesTenium therapeuticTorrey pines based

Sanofi bets $1 7b on potential best-in-class rare disease therapy

Sanofi bets $1 7b on potential best-in-class rare disease therapy
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

Phouman ashrafianHead of researchInhibrx incNew inhibrx

Press Release: Sanofi to acquire Inhibrx, Inc , adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline -January 23, 2024 at 01:31 am EST

Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline Acquisition supports Sanofi’s portfolio growth.

France generalTimothy gilbertSally bainEva schaefer jansenTarik elgoutniSandrine guendoulCorentine driancourtMarkp lappeFelix lauscherNathalie phamPhouman ashrafianHead of researchInhibrx incGotshal mangesCenterview partnersExchange commission

Sanofi - Aventis Groupe: Press Release: Sanofi to acquire Inhibrx, Inc , adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline

Sanofi - Aventis Groupe: Press Release: Sanofi to acquire Inhibrx, Inc , adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

France generalSally bainCorentine driancourtSandrine guendoulEva schaefer jansenNathalie phamStefan klotterMarkp lappeFelix lauscherTimothy gilbertTarik elgoutniPhouman ashrafianCenterview partnersHead of researchExchange commissionInhibrx inc

Sanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2 2 Billion -- Update

By Dominic Chopping and Fabiana Negrin Ochoa Sanofi plans to buy assets from biopharmaceutical company Inhibrx in a deal worth up to $2.2 billion as it looks to diversify its product base and.

Phouman ashrafianPaul hudsonFabiana negrin ochoaAmbrx biopharmaDominic choppingChief executive paul hudsonCalifornia based inhibrxHarpoon therapeuticsDow jones